Bridgebio Oncology Therapeutics Inc (BBOT)

10:19 AM

BridgeBio Oncology stock initiated with Outperform rating at Raymond James By Investing.com - Investing.com Nigeria

10:19 AM

07:18 AM

Raymond James Initiates BridgeBio Oncology Therapeutics at Outperform With $24 Price Target - MarketScreener

07:18 AM

06:55 AM

BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com

06:55 AM

Jan 08, 2026

BridgeBio Oncology stock price target raised to $32 from $25 at Leerink - Investing.com Canada

Jan 08, 2026

Jan 07, 2026

Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock By Investing.com - Investing.com UK

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley - Investing.com

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley By Investing.com - Investing.com India

Jan 07, 2026

Jan 07, 2026

BBOT: Promising efficacy and safety for three RAS-pathway inhibitors, with key data expected in 2026 - TradingView — Track All Markets

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology reports positive data from RAS-pathway cancer trials - Investing.com

Jan 07, 2026

Jan 07, 2026

BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs - TradingView — Track All Markets

Jan 07, 2026

Jan 07, 2026

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs - The Manila Times

Jan 07, 2026

Jan 07, 2026

BBOT Announces New Clinical Data Advancing Its Portfolio of - GlobeNewswire

Jan 07, 2026

Jan 02, 2026

BridgeBio Oncology Therapeutics, Inc.Common Stock (NQ: BBOT - FinancialContent

Jan 02, 2026

Dec 21, 2025

BridgeBio Oncology Therapeutics, Inc.(NasdaqGM: BBOT) added to S&P Global BMI Index - marketscreener.com

Dec 21, 2025

Dec 19, 2025

BridgeBio Oncology Therapeutics Earnings Notes - Trefis

Dec 19, 2025

Dec 16, 2025

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2025

Dec 15, 2025

Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance

Dec 15, 2025

Dec 15, 2025

Wedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - MSN

Dec 15, 2025

Dec 12, 2025

BridgeBio Oncology Therapeutics (BBOT) updates CEO option grant terms - Stock Titan

Dec 12, 2025

Dec 12, 2025

BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha

Dec 12, 2025

Dec 12, 2025

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 12, 2025

Dec 11, 2025

Wedbush Reiterates Outperform Rating for BBOT; Price Target Unch - GuruFocus

Dec 11, 2025

Dec 11, 2025

BridgeBio Oncology initiated with an overweight at Morgan Stanley - MSN

Dec 11, 2025

Dec 10, 2025

BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga

Dec 10, 2025

Dec 10, 2025

BridgeBio Oncology Therapeutics, Inc. Announces Late-Breaking Preclinical Data on BBO-10203, a First-In-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium - marketscreener.com

Dec 10, 2025

Dec 10, 2025

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, - GlobeNewswire

Dec 10, 2025

Dec 08, 2025

BridgeBio Oncology stock reaches all-time high at 14.87 USD By Investing.com - Investing.com Canada

Dec 08, 2025

Dec 08, 2025

BridgeBio Oncology stock reaches all-time high at 14.87 USD - Investing.com India

Dec 08, 2025

Dec 05, 2025

Morgan Stanley Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Overweight Recommendation - Nasdaq

Dec 05, 2025

Dec 05, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Dec 05, 2025

Dec 05, 2025

BridgeBio Oncology: Positioned for Growth with Innovative RAS-Targeted Therapies - TipRanks

Dec 05, 2025

Dec 05, 2025

Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com

Dec 05, 2025

Dec 05, 2025

BridgeBio Oncology initiated with an Overweight at Morgan Stanley - TipRanks

Dec 05, 2025

Dec 05, 2025

Morgan Stanley initiates coverage on BridgeBio Oncology stock with Overweight rating - Investing.com India

Dec 05, 2025

Dec 03, 2025

BBOT: All three oncology programs progressed in 2025, with major data readouts and strategic decisions set for 2026 - TradingView — Track All Markets

Dec 03, 2025

Nov 25, 2025

BBOT: Wedbush Reiterates Outperform Rating with $25 Target | BBO - GuruFocus

Nov 25, 2025

Nov 21, 2025

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail

Nov 21, 2025

Nov 19, 2025

BBOT to Participate in Upcoming December Investor Healthcare Conferences - The Manila Times

Nov 19, 2025

Nov 18, 2025

BridgeBio Oncology Therapeutics Reports Q3 2025 Progress - TipRanks

Nov 18, 2025

Nov 16, 2025

Oppenheimer Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛

Nov 16, 2025

Nov 16, 2025

BridgeBio Oncology Therapeutics, Inc. (BBOT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Nov 16, 2025

Nov 15, 2025

Decoding BridgeBio Oncology Therapeutics Inc (BBOT): A Strategic SWOT Insight - GuruFocus

Nov 15, 2025

Nov 13, 2025

Oppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq

Nov 13, 2025

Nov 13, 2025

BBOT Analyst Rating Update: Oppenheimer Lowers Price Target | BB - GuruFocus

Nov 13, 2025

Nov 13, 2025

Oppenheimer Adjusts BridgeBio Oncology Therapeutics Price Target to $22 From $23, Maintains Outperform Rating - MarketScreener

Nov 13, 2025

Nov 12, 2025

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - The Manila Times

Nov 12, 2025

Nov 12, 2025

A breakup strategy that’s inspiring clinical candidates for cancer - Chemical & Engineering News

Nov 12, 2025

Nov 12, 2025

BridgeBio Oncology Therapeutics, Inc.'s (NASDAQ:BBOT) largest shareholders are individual investors who were rewarded as market cap surged US$51m last week - Yahoo Finance

Nov 12, 2025

Nov 07, 2025

Analysts Are Bullish on Top Healthcare Stocks: CytomX Therapeutics (CTMX), AbCellera Biologics (ABCL) - The Globe and Mail

Nov 07, 2025